Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
18 studies found for:    kw-0761
Show Display Options
Rank Status Study
1 Recruiting A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
Condition: Advanced/Metastatic Solid Tumors
Interventions: Drug: PF-05082566;   Drug: KW-0761
2 Completed
Has Results
Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma
Condition: Adult T-cell Leukemia-lymphoma
Intervention: Biological: KW-0761
3 Completed Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Conditions: Peripheral T-cell Lymphoma;   Cutaneous T-cell Lymphoma
Intervention: Biological: KW-0761
4 Active, not recruiting Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.
Condition: Solid Tumor
Intervention: Biological: Mogamulizumab
5 Recruiting Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Conditions: Advanced Solid Tumors;   Metastatic Solid Tumors
Intervention: Biological: Mogamulizumab (KW-0761)
6 Completed Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma
Condition: Peripheral T/NK-cell Lymphoma
Intervention: Biological: KW-0761
7 Completed Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761 (mogamulizumab)
8 Completed Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761
9 Active, not recruiting Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Condition: Cutaneous T-Cell Lymphoma
Interventions: Biological: KW-0761;   Drug: Vorinostat
10 Completed
Has Results
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
Conditions: Adult T-Cell Leukemia and Lymphoma (ATL);   Adult Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: KW-0761
11 Completed Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
Condition: Adult T-cell Leukemia-Lymphoma
Interventions: Drug: VCAP/AMP/VECP(mLSG15);   Biological: KW-0761
12 Active, not recruiting Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Biological: mogamulizumab;   Drug: Docetaxel
13 Recruiting Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Conditions: Gastric Cancer;   Esophageal Cancer;   Lung Cancer;   Renal Cancer
Interventions: Biological: Mogamulizumab;   Biological: Nivolumab
14 Recruiting Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Conditions: Solid Tumor;   Cancer;   Carcinoma
Intervention: Biological: Mogamulizumab + Nivolumab
15 Recruiting KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Solid Tumor;   Cancer;   Carcinoma
Interventions: Drug: KHK2455;   Drug: Mogamulizumab
16 Recruiting Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Biological: mogamulizumab;   Biological: MEDI4736;   Biological: tremelimumab
17 Active, not recruiting KW 0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Condition: Adult T-cell Leukemia-Lymphoma
Interventions: Biological: KW-0761;   Drug: investigator's choice (pralatrexate; gemcitabine/oxaliplatin; dexamethasone/cisplatin/cytarabine)
18 Recruiting Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
Condition: Solid Tumor
Intervention: Biological: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)

Study has passed its completion date and status has not been verified in more than two years.